AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19570764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with potassium canrenoate (200 mg/day, increased to 400 mg/day) and furosemide (50 mg/day, increased to 150 mg/day)
Number of subjects: 100
Study 19570764 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 100
Study 19570764 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 100
Study 17920481 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted implantation
Number of subjects: 72
Study 17920481 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual implantation
Number of subjects: 72
Study 16343028 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid
Number of subjects: 31
Study 16343028 — intervention group
Group type: COMPARATOR
Intervention: 0.5% anthralin
Number of subjects: 31
Study 12213433 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnitine treatment
Number of subjects: 24
Study 10541084 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor display format
Number of subjects: 4
Study 10541084 — intervention group
Group type: COMPARATOR
Intervention: Film display format
Number of subjects: 4
Study 7848124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial irradiation plus intrathecal methotrexate sodium
Number of subjects: 74
Study 7848124 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methotrexate alone
Number of subjects: 74
Study 1983347 — intervention group
Group type: EXPERIMENTAL
Intervention: sufotidine 600 mg nocte
Number of subjects: 12
Study 1983347 — intervention group
Group type: EXPERIMENTAL
Intervention: sufotidine 600 mg b.d.
Number of subjects: 12
Study 1983347 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 698177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicellulose
Number of subjects: 8
Study 698177 — intervention group
Group type: EXPERIMENTAL
Intervention: Raffinose
Number of subjects: 8
Study 698177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 8
Study 698177 — intervention group
Group type: COMPARATOR
Intervention: Cellulose
Number of subjects: 8
Study 698177 — intervention group
Group type: COMPARATOR
Intervention: Pectin
Number of subjects: 8
Study 698177 — intervention group
Group type: COMPARATOR
Intervention: Lignin
Number of subjects: 8
Study 31018210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural cryobiopsy (CB)
Number of subjects: 50
Study 31018210 — intervention group
Group type: COMPARATOR
Intervention: Flexible forceps biopsy (FFB)
Number of subjects: 50
Study 28715907 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prolonged exposure treatment
Number of subjects: 66
Study 28715907 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 66
Study 26481666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Gliding
Number of subjects: 45
Study 26481666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Stretching
Number of subjects: 45
Study 26481666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23222915 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tadalafil 5 mg for 12 weeks
Number of subjects: 0
Study 23222915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21972857 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE program (4-session self-regulation curriculum)
Number of subjects: 58
Study 21972857 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 58
Study 18077191 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-EVR
Number of subjects: 65
Study 18077191 — intervention group
Group type: COMPARATOR
Intervention: Open Aneurysm Repair (OR)
Number of subjects: 65
Study 18077191 — intervention group
Group type: COMPARATOR
Intervention: Colorectal Resection (CR)
Number of subjects: 65
Study 15721417 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT (cisplatin 70 mg/m2 plus fluorouracil 1000 mg/m2 every 3 weeks for four cycles)
Number of subjects: 243
Study 15721417 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 243
Study 15721417 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CT
Number of subjects: 243
Study 12033095 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution (5.5-8 mL.kg-1 blood withdrawn before induction, replaced by colloids)
Number of subjects: 38
Study 12033095 — intervention group
Group type: COMPARATOR
Intervention: Control (no haemodilution)
Number of subjects: 38
Study 12033095 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution
Number of subjects: 38
Study 12033095 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 10456309 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position
Number of subjects: 240
Study 10456309 — intervention group
Group type: COMPARATOR
Intervention: Lithotomy position
Number of subjects: 240
Study 7799116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and methylprednisolone
Number of subjects: 0
Study 1971708 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of propafenone every eight hours for five days
Number of subjects: 14
Study 1971708 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg of propafenone every eight hours for five days
Number of subjects: 14
Study 1971708 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of propafenone every eight hours for five days
Number of subjects: 14
Study 1971708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 693750 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing a dynamometer during stimulus presentations
Number of subjects: 20
Study 693750 — intervention group
Group type: COMPARATOR
Intervention: No dynamometer squeezing (control group)
Number of subjects: 20
Study 31823812 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth plus standard of care (motivational interviewing plus tooth scaling and polishing)
Number of subjects: 86
Study 31823812 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (motivational interviewing plus tooth scaling and polishing)
Number of subjects: 86
Study 31823812 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 86
Study 29200757 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,064-nm Nd:YAG laser therapy and amorolfine nail lacquer
Number of subjects: 128
Study 29200757 — intervention group
Group type: COMPARATOR
Intervention: Topical amorolfine lacquer monotherapy
Number of subjects: 128
Study 26386748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cancer Recovery (MBCR)
Number of subjects: 72
Study 26386748 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy for Insomnia (CBT-I)
Number of subjects: 72
Study 26386748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness facets (acting with awareness, non-judging, non-reacting)
Number of subjects: 72
Study 26386748 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MBCR and CBT-I
Number of subjects: 72
Study 24169300 — intervention group
Group type: EXPERIMENTAL
Intervention: The11 injury prevention program
Number of subjects: 456
Study 24169300 — intervention group
Group type: COMPARATOR
Intervention: Usual warm-up routines (Control)
Number of subjects: 456
Study 20574108 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation for 4 weeks
Number of subjects: 10
Study 20574108 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 2 weeks followed by 2 weeks of real rTMS stimulation
Number of subjects: 10
Study 19204602 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise program (8-12 weeks ramp-up followed by 12 weeks of exercise, approximately 228 min/week at 40-60% peak VO2, n = 21)
Number of subjects: 37
Study 19204602 — intervention group
Group type: COMPARATOR
Intervention: Control (no change in lifestyle, n = 16)
Number of subjects: 37
Study 17285234 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by general practitioners
Number of subjects: 338
Study 17285234 — intervention group
Group type: COMPARATOR
Intervention: Follow-up by surgeons
Number of subjects: 338
Study 17285234 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 338
Study 17285234 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners and surgeons
Number of subjects: 338
Study 17285234 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Dukes stage
Number of subjects: 338
Study 17285234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient choice of follow-up setting
Number of subjects: 338
Study 14625698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair (n=126)
Number of subjects: 247
Study 14625698 — intervention group
Group type: COMPARATOR
Intervention: Read‐Rives repair (n=121)
Number of subjects: 247
Study 11176912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg once daily for 7 days
Number of subjects: 955
Study 11176912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study 9589380 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (6 g, reduced to 3 g from day +30)
Number of subjects: 42
Study 9589380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 42
Study 8113551 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus antiplatelet therapy
Number of subjects: 195
Study 8113551 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 195
Study 3072969 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAVE
Number of subjects: 62
Study 3072969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 29617058 — intervention group
Group type: EXPERIMENTAL
Intervention: EDX110
Number of subjects: 135
Study 29617058 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 29184579 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support program (6 sessions, 1 hour each)
Number of subjects: 64
Study 29184579 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 sessions held by the researcher)
Number of subjects: 64
Study 26345129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% flutamide cream
Number of subjects: 74
Study 26345129 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 74
Study 24099334 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (remote exchange of vital signs and symptoms data)
Number of subjects: 3230
Study 24099334 — intervention group
Group type: COMPARATOR
Intervention: Usual care (excluding telehealth)
Number of subjects: 3230
Study 24099334 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 3230
Study 24099334 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3230
Study 20308941 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed information package containing guideline recommendations for the management of LBP (n = 876)
Number of subjects: 1758
Study 20308941 — intervention group
Group type: COMPARATOR
Intervention: No intervention (n = 882)
Number of subjects: 1758
Study 18407022 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual computer program
Number of subjects: 80
Study 18407022 — intervention group
Group type: COMPARATOR
Intervention: Commercial information leaflet
Number of subjects: 80
Study 15637977 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-dosing regimen (2 doses at the start of brushing with 1 additional in-mouth dose during the last 30 seconds of brushing [2+1])
Number of subjects: 18
Study 15637977 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (2 doses at the start of brushing only [2+0])
Number of subjects: 18
Study 11561033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman voice treatment (LSVT)
Number of subjects: 33
Study 11561033 — intervention group
Group type: COMPARATOR
Intervention: Respiratory therapy (RET)
Number of subjects: 33
Study 9491946 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without critical coronary narrowing
Number of subjects: 64
Study 9491946 — intervention group
Group type: COMPARATOR
Intervention: Patients with critical coronary narrowing
Number of subjects: 64
Study 8018578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen for small cell lung cancer
Number of subjects: 0
Study 8018578 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy regimen for non-small cell lung cancer
Number of subjects: 0
Study 8018578 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted comparisons of clinician experience
Number of subjects: 0
Study 3364218 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco use
Number of subjects: 0
Study 3364218 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 29094957 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 56
Study 29094957 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 56
Study 26799502 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training (BPT)
Number of subjects: 26
Study 26799502 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal stimulant medication (MSM)
Number of subjects: 26
Study 26799502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined BPT+MSM
Number of subjects: 26
Study 26799502 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-scale SMART
Number of subjects: 26
Study 24450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Number of subjects: 30
Study 24450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Number of subjects: 30
Study 24450367 — intervention group
Group type: COMPARATOR
Intervention: Nonmanipulation (control)
Number of subjects: 30
Study 22524350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participatory music class
Number of subjects: 100
Study 22524350 — intervention group
Group type: COMPARATOR
Intervention: Passive music experience while playing
Number of subjects: 100
Study 20103072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonphysician skills coach
Number of subjects: 49
Study 20103072 — intervention group
Group type: COMPARATOR
Intervention: Faculty surgeon
Number of subjects: 49
Study 18022319 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 405
Study 18022319 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 405
Study 16181233 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 9
Study 16181233 — intervention group
Group type: COMPARATOR
Intervention: 1 ml saline
Number of subjects: 9
Study 11562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling from a genetic counselor
Number of subjects: 72
Study 11562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Education from an interactive computer program followed by individualized counseling
Number of subjects: 72
Study 11562929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 9634323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 lubricated condoms
Number of subjects: 635
Study 9634323 — intervention group
Group type: COMPARATOR
Intervention: Plain silicone lubricated condoms
Number of subjects: 635
Study 7875114 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (50 mg/day)
Number of subjects: 133
Study 7875114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 3349981 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 3349981 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine combined with Propranolol
Number of subjects: 11
Study 3349981 — intervention group
Group type: COMPARATOR
Intervention: Control (without intervention)
Number of subjects: 11
Study 31961377 — intervention group
Group type: EXPERIMENTAL
Intervention: Default quantities of opioids changed from 12 and 20 tablets to null, 5, 10, and 15 tablets.
Number of subjects: 104
Study 31961377 — intervention group
Group type: COMPARATOR
Intervention: Lower default quantities (e.g., 5 vs 15 tablets).
Number of subjects: 104
Study 31961377 — intervention group
Group type: EXPERIMENTAL
Intervention: Default settings in the EMR.
Number of subjects: 104
Study 31336610 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological integration methods
Number of subjects: 319
Study 31336610 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing technology integration
Number of subjects: 319
Study 27473633 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light treatment (1 hour for 6 days)
Number of subjects: 10
Study 27473633 — intervention group
Group type: COMPARATOR
Intervention: Evening light treatment (1 hour for 6 days)
Number of subjects: 10
Study 27473633 — intervention group
Group type: EXPERIMENTAL
Intervention: Both morning and evening light treatments
Number of subjects: 10
Study 27473633 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light treatment
Number of subjects: 10
Study 26090395 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids and Meriva (curcumin) at 2 g per day for 12 weeks
Number of subjects: 63
Study 26090395 — intervention group
Group type: COMPARATOR
Intervention: Topical steroids alone for 12 weeks
Number of subjects: 63
Study 23852883 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestible participants
Number of subjects: 129
Study 23852883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-suggestible participants
Number of subjects: 129
Study 23852883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 129
Study 21453658 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 63
Study 21453658 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 63
Study 19540105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg t.i.d.) + Vitamin E (100 mg t.i.d.)
Number of subjects: 83
Study 19540105 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Vitamin E (100 mg t.i.d.)
Number of subjects: 83
Study 16431252 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone alternated with a cytotoxic drug every other month for 6 months (group A)
Number of subjects: 32
Study 16431252 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic adrenocorticotropic hormone administered twice a week for 1 year (group B)
Number of subjects: 32
Study 15571446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-moderate (.70 gm alcohol/kg body weight)
Number of subjects: 60
Study 15571446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-low (.35 gm alcohol/kg body weight)
Number of subjects: 60
Study 15571446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15571446 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 15571446 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived intoxication
Number of subjects: 60
Study 11694408 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo and G-CSF
Number of subjects: 18
Study 11694408 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 18
Study 9212116 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 50 microg/kg intravenously (n = 8)
Number of subjects: 37
Study 9212116 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 50 microg/kg + 0.5 microg x kg(‐1) x min(‐1) (n = 10)
Number of subjects: 37
Study 9212116 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 75 microg/kg + 0.75 microg x kg(‐1) x min(‐1) (n = 9)
Number of subjects: 37
Study 9212116 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 37
Study 7965243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail with prepaid postage
Number of subjects: 146
Study 7965243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail
Number of subjects: 146
Study 7965243 — intervention group
Group type: COMPARATOR
Intervention: Hand delivery
Number of subjects: 146
Study 30176174 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership including an industry partner, university partner, and NGO partner with COI-mitigation processes (arm's-length process, independent advisory board, open data commitment)
Number of subjects: 2339
Study 30176174 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero, one, two, or three COI-mitigation procedures in a partnership of a university and either an NGO or industry partner
Number of subjects: 2339
Study 29420766 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO® System with proximal tibia approach
Number of subjects: 77
Study 29420766 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO® System with proximal humerus approach
Number of subjects: 77
Study 29420766 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ‐IO® System
Number of subjects: 77
Study 27687403 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined liner of pharyngeal airway (SLIPA) in nonparalyzed patients (group NR)
Number of subjects: 80
Study 27687403 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined liner of pharyngeal airway (SLIPA) in paralyzed patients (group R)
Number of subjects: 80
Study 27687403 — intervention group
Group type: COMPARATOR
Intervention: Streamlined liner of pharyngeal airway (SLIPA)
Number of subjects: 80
Study 25405478 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin Outreach Support (SOS) intervention
Number of subjects: 7586
Study 25405478 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7586
Study 22505248 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent hemodialysis (six times per week)
Number of subjects: 6276
Study 22505248 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (three times per week)
Number of subjects: 6276
Study 20304348 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 20 mg
Number of subjects: 150
Study 20304348 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg
Number of subjects: 150
Study 20304348 — intervention group
Group type: COMPARATOR
Intervention: normal saline (Group NS)
Number of subjects: 150
Study 17768687 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-oriented vocational therapy group
Number of subjects: 227